Finally, the most recent systematic review and meta-analysis [77] specifically looked at patients with pre-existing inflammatory bowel disease (IBD), and approximately 40% of the examined patients with melanoma experienced IBD relapse with ICIs, with most relapsing patients requiring corticosteroids and a third requiring biologics such as tumor necrosis factor (TNF) blockers. Here, TNF is linked to melanoma.